|Tomorrow’s Cancer Treatment Today|
It was our pleasure to announce that the "ZMKS ACTL tumor cell targeting therapy technology Seminar" was successfully on April 21st held in Beijing
With the anticipation of WHO in the near 2020, the number of cancer patients will be reaching 20 millions from all over the world, and go up to 12 millions of people dying from this deadly disease. As cancer will be the number one killer in the next century. Causes with estimate of 1.3 million of death and 1.6 million of incidences.
Cancer is one of the most deadly diseases, in order to flight this disease, our medical researchers have been devoting their best effort into it. With the latest technological development of immunology, molecular biology, biotechnology, tumor cell targeting therapy is now commonly recognized as the Forth anti-cancer therapy by all those working in the field of cancer-care and research, after the traditional surgery, radiotherapy and chemotherapy.
Prof. Liu Yong was presenting his speech and answering the technical questions from the audiences
Professor Yong Liu and his research team from United States were cordially invited by Cancer Therapy China to provide a comprehensive overview of the ACTTM Therapy, at this National Oncologist Conference --- "ACTLTM Tumor Cell Targeting Therapy Seminar". With the attendance of more than hundreds of oncologists from domestic and overseas. Mr. Shelton Stinger, who happens to be one our patients, was also invited from Los Angeles to join up this meeting.
Dr. Calvin Li, the Managing Director of ZMKS International Cancer Therapy biotechnologies LTD clearly outlining the mechanism
The Canadian scientist, member of Institute of Medicine and National Academy of Science in the US, Professor Ralph M. Steinman, was awarded as one of the Nobel Laureates in Medicine according to the “Discovery of the dendritic cell (DC cell) and its role in the adaptive immune system”. In the early 21st century, under the supervision of Professor Steinman in Stanford Cancer Institute in the US, Professor Yong LIU combined his research in Recombinant Adeno-associated Virus (rAAV) with the work of Professor Steinman to develop a type of rAAV transfected DC cells which could carry one or several type of tumor-associated epitopes determinant gene(s). This therapeutic technology is the avoidance of side-effects and the reversal of drug-resistance developed by cancer cells in fighting against hormonal and biological targeting drug treatments.
Professor Liu Yong was interviewing by the CNTV network
What is Tumor Cell Targeting Therapy (ACTLTM)?AAV-DC-CTLTM Tumor Cell Targeting Therapy technology makes use of the non-pathogenic wild-type Adeno-associated virus (AAV), through gene recombination technique, to construct a recombinant AAV carrying specific tumor-associated epitope determinant gene(s). After the infection of the recombinant AAV to the peripheral blood monocular cells of the cancer patent and cytokine induction aft wards, monocytes would transform to the powerful antigen presenting DC cells. Subsequently, the DC cells obtained through such technology can in vitro elicit the T lymphocytes extracted from patient and produce effective anti-tumor cytotoxic T lymphocytes (CTL). Since the CTL produced possess tumor antigen specificity, i.e. targeting ability, therefore, one or several types of specific anti-tumor related antigen positive tumor cells and PSMA positive angiogenesis tumor endothelial cells would be eliminated. As such, antigen negative cells would not be affected.